Case Study: iTeos Therapeutics SA advances cancer immunotherapy research with Molecular Devices multi-mode microplate readers

iTeos Therapeutics SA runs 10x384 plates/day with Molecular Devices

iTeos Therapeutics SA, a Belgium-based biotech company, required robust microplate readers for their research into next-generation cancer immunotherapies. Their challenge was to find systems that could perform a variety of biochemical and cellular assays with the highest quality and reproducibility for both everyday use and high-throughput analysis of novel therapeutic targets. They turned to Molecular Devices for a solution.

Molecular Devices provided iTeos with the SpectraMax i3x and SpectraMax Paradigm Multi-Mode Microplate Readers. The cartridge-based systems delivered the flexibility and reliability needed, with the Paradigm model serving as a high-throughput workhorse for screening approximately ten 384-well plates per day. The results enabled iTeos to reliably identify and test new immuno-oncology therapeutics, advancing their mission to benefit cancer patients.

iTeos Therapeutics SA